Profile data is unavailable for this security.
About the company
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
- Revenue in USD (TTM)1.15m
- Net income in USD-36.38m
- Incorporated2003
- Employees27.00
- LocationOncternal Therapeutics Inc12230 EL CAMINO REAL, SUITE 230SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 434-1113
- Fax+1 (858) 408-3010
- Websitehttps://www.oncternal.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lisata Therapeutics Inc | 0.00 | -20.05m | 23.01m | 25.00 | -- | 0.5352 | -- | -- | -2.46 | -2.46 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -35.01 | -45.97 | -38.40 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -35.58m | 23.34m | 14.00 | -- | -- | -- | -- | -2.64 | -2.64 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -118.12 | -- | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | -- | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Lyra Therapeutics Inc | 1.68m | -68.88m | 23.35m | 109.00 | -- | 0.3013 | -- | 13.90 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 24.37m | 298.00 | -- | 0.5694 | -- | 0.5244 | -0.2176 | -0.2176 | 1.30 | 1.20 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| NanoViricides Inc | 0.00 | -9.36m | 24.38m | 7.00 | -- | 2.11 | -- | -- | -0.8004 | -0.8004 | 0.00 | 0.9828 | 0.00 | -- | -- | 0.00 | -55.47 | -43.54 | -57.90 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Unity Biotechnology Inc | 0.00 | -34.78m | 24.85m | 19.00 | -- | 1.04 | -- | -- | -2.33 | -2.33 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -40.18 | -47.21 | -48.47 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| NKGen Biotech Inc | 0.00 | -82.95m | 25.19m | 63.00 | -- | -- | -- | -- | -3.63 | -3.63 | 0.00 | -2.57 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.6077 | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| Acasti Pharma Inc | 0.00 | -38.77m | 25.28m | 32.00 | -- | 0.3909 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| TherapeuticsMD Inc | 1.20m | -6.20m | 25.60m | 1.00 | -- | 0.8931 | -- | 21.35 | -0.58 | -0.6955 | 0.1103 | 2.49 | 0.0236 | -- | 0.4556 | 1,199,000.00 | -12.19 | -53.35 | -16.34 | -111.61 | 73.89 | 86.67 | -516.93 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Oncternal Therapeutics Inc | 1.15m | -36.38m | 25.63m | 27.00 | -- | 1.12 | -- | 22.27 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 25.99m | 3.00 | -- | 0.9906 | -- | 60.24 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Biora Therapeutics Inc | 4.00k | -124.33m | 26.18m | 58.00 | -- | -- | -- | 6,546.11 | -8.57 | -8.56 | 0.0003 | -4.28 | 0.00009 | -- | 0.0048 | 68.97 | -293.45 | -122.84 | -- | -369.01 | -- | -- | -3,108,350.00 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| bioAffinity Technologies Inc | 2.53m | -7.94m | 26.35m | 75.00 | -- | 4.37 | -- | 10.40 | -0.9036 | -0.9036 | 0.2895 | 0.5168 | 0.2482 | 144.95 | 6.16 | 33,766.67 | -77.80 | -- | -93.28 | -- | 31.26 | -- | -313.41 | -- | 1.76 | -- | 0.1983 | -- | 52,660.42 | -- | 2.66 | -- | -- | -- |
| Singular Genomics Systems Inc | 2.49m | -96.21m | 28.17m | 255.00 | -- | 0.1801 | -- | 11.31 | -1.31 | -1.31 | 0.034 | 2.12 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Oncternal Therapeutics Inc's reporting currency: US Dollar USD
14.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 142.21k | 4.81% |
| Millennium Management LLCas of 31 Dec 2023 | 102.80k | 3.47% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 39.28k | 1.33% |
| Quantum Private Wealth LLCas of 31 Mar 2024 | 27.81k | 0.94% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 25.89k | 0.88% |
| Richmond Brothers, Inc.as of 31 Mar 2024 | 24.70k | 0.83% |
| BIT Capital GmbHas of 30 Oct 2022 | 20.85k | 0.70% |
| Brighton Jones LLCas of 31 Mar 2024 | 16.92k | 0.57% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 16.36k | 0.55% |
| G1 Execution Services LLCas of 31 Mar 2024 | 10.19k | 0.34% |
More ▼
Data from 31 Aug 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
